These observations suggested that the preexisting CD99+CD49d+CD52+Galectin-1+ (QSCs) cells at diagnosis were chemoresistant, and these cells were further enriched in the persisting residual AML cells. The gene discussed is CD52; the disease is acute myeloid leukemia.